DJIA 17,172.68 -107.06 -0.62%
NASDAQ 4,527.69 -52.10 -1.14%
S&P 500 1,994.29 -16.11 -0.80%
market minute promo

Cubist Pharmaceuticals (NASDAQ: CBST)



company name or ticker
Company Photos
(Click to zoom)

Benzinga's Top #PreMarket Gainers

Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Suc

Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix

Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium

Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog

Companies Betting on the Next 10 Blockbuster Drugs

Cubist Pharmaceuticals' CEO Discusses Q1 2014 Results - Earnings Call Transcript

This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value

Instead of sitting back and waiting to be purchased, AstraZeneca could bolster shareholder value by going on the offensive.

Interesting CBST Put And Call Options For June 21st

Emerging 'Superbugs' -- and Why Investors Should Care

Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/taz

Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam
See More Articles...